Vanguard Group Inc. Has $72.66 Million Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Vanguard Group Inc. reduced its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 2.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,314,372 shares of the specialty pharmaceutical company's stock after selling 33,739 shares during the quarter. Vanguard Group Inc. owned about 6.25% of ANI Pharmaceuticals worth $72,658,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. US Bancorp DE lifted its holdings in shares of ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after buying an additional 531 shares during the last quarter. KBC Group NV increased its holdings in shares of ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after purchasing an additional 600 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at about $166,000. HighTower Advisors LLC acquired a new stake in ANI Pharmaceuticals during the third quarter worth about $222,000. Finally, China Universal Asset Management Co. Ltd. increased its stake in ANI Pharmaceuticals by 10.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after acquiring an additional 412 shares during the period. 76.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ANIP has been the topic of a number of recent research reports. StockNews.com downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, April 8th. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Guggenheim restated a "buy" rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. Finally, Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday, March 14th. They issued a "buy" rating and a $80.00 price objective for the company. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $79.75.

ANI Pharmaceuticals Trading Down 0.9 %

Shares of ANI Pharmaceuticals stock traded down $0.65 during trading on Wednesday, reaching $68.91. 8,774 shares of the company were exchanged, compared to its average volume of 268,239. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -125.21 and a beta of 0.49. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $70.79. The business has a 50-day moving average price of $62.71 and a 200-day moving average price of $59.22. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

Insider Buying and Selling

In related news, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the sale, the senior vice president now directly owns 66,525 shares of the company's stock, valued at approximately $4,048,711.50. This represents a 1.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Meredith Cook sold 400 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the transaction, the vice president now owns 80,545 shares of the company's stock, valued at $5,100,914.85. This trade represents a 0.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,200 shares of company stock valued at $197,792 in the last 90 days. 12.70% of the stock is owned by insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.